William C. Roberts
Investor Relations Contact at G1 THERAPEUTICS, INC.
Profile
William C.
Roberts is currently the VP-Investor Relations & Corporate Communications at G1 Therapeutics, Inc. Prior to this, he held positions as Vice President-Communications & Investor Relations at Shire ViroPharma, Inc., Vice President-Investor Relations & Communications at Zynerba Pharmaceuticals, Inc., Head-Investor Relations at Medimmune, Inc., Vice President-Investor Relations at Adaptimmune Therapeutics Plc, and Vice President-Corporate Communications at Viropharma, Inc. Mr. Roberts received his undergraduate degree from the University of Virginia and his MBA from Keller Graduate School of Management.
William C. Roberts active positions
| Companies | Position | Start |
|---|---|---|
| G1 THERAPEUTICS, INC. | Investor Relations Contact | 03/01/2021 |
Former positions of William C. Roberts
| Companies | Position | End |
|---|---|---|
| ADAPTIMMUNE THERAPEUTICS PLC | Investor Relations Contact | 22/10/2017 |
| Viropharma, Inc. | Public Communications Contact | - |
| ZYNERBA PHARMACEUTICALS, INC. | Investor Relations Contact | - |
| Medimmune, Inc. | Investor Relations Contact | - |
Shire ViroPharma, Inc.
 Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA. | Investor Relations Contact | - |
Training of William C. Roberts
| Keller Graduate School of Management | Masters Business Admin |
| University of Virginia | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| ADAPTIMMUNE THERAPEUTICS PLC | Health Technology |
| ZYNERBA PHARMACEUTICALS, INC. | Health Technology |
| G1 THERAPEUTICS, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Shire ViroPharma, Inc.
Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA. | Health Technology |
| Medimmune, Inc. | Health Technology |
| Viropharma, Inc. |
- Stock Market
- Insiders
- William C. Roberts
